|
|
|
|
||
Buy
Re: Zinc Finger vs CRISPR publications (MineMan)I think you are right. I am sure that any new agreement would include performance goals, and maybe fines for non performance. Any new deal more likely not with Shire. Their new CEO prefers to own the IP rather than license it. Huntington's should be in CTs already, another example of Shire dragging their feet. Anyone remember when the Shire agreement is scheduled to expire? I doubt that SGMO will offer an extension. Possible but not likely. IMO. Huntington's and Parkinson's would be nice additions to SGMO pre clinical programs. 6 year agreement, started spring 2012? SGMO and other collaborators, besides Shire, have plenty on their plate to move into CTs for the next several years. SGMO best kept secret on main street. Still the Rodney Daingerfield of Biotech. Soon to change. SOON is of coarse relative "B" |
return to message board, top of board |